Potential liabilities were assessed by determining the inhibition of the hERG potassium channel, five isoforms of CYP450 (1A2, 2C9, 2C19, 2D6 and 3A4), cytotoxicity against A459 cells (human lung adenocarcinoma epithelial cell line) and mitochondrial toxiticity against 786-O cells (renal carcinoma cell line) for all compounds at a concentration of 10 µM. The results are shown in Figure . Further, the compounds were assessed for and passed a check for being Pan-assay interference compounds (PAINS).